PUBLISHER: Lucintel | PRODUCT CODE: 1386082
PUBLISHER: Lucintel | PRODUCT CODE: 1386082
The future of the global cancer biomarkers market looks promising with opportunities in the diagnostics, R&D, prognostics, and risk management markets. The global cancer biomarkers market is expected to reach an estimated $37.7 billion by 2030 with a CAGR of 14.5% from 2024 to 2030. The major drivers for this market are increasing inclination towards personalized medicine for cancer treatment, growing awareness towards importance of early detection of cancer, and rising government support for cancer research.
A more than 150-page report is developed to help in your business decisions.
The study includes a forecast for the global cancer biomarkers by type, cancer, profiling technology, application, and region.
Cancer Biomarkers Market by Type [Shipment Analysis by Value from 2018 to 2030]:
Cancer Biomarkers Market by Cancer [Shipment Analysis by Value from 2018 to 2030]:
Cancer Biomarkers Market by Profiling Technology [Shipment Analysis by Value from 2018 to 2030]:
Cancer Biomarkers Market by Application [Shipment Analysis by Value from 2018 to 2030]:
Cancer Biomarkers Market by Region [Shipment Analysis by Value from 2018 to 2030]:
Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies cancer biomarkers companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the cancer biomarkers companies profiled in this report include-
Lucintel forecasts that breast cancer will remain the largest segment over the forecast period due to increasing incidence of breast cancer and rising awareness of the diagnosis of this disease.
Within this market, diagnostic will remain the largest segment due to increasing prevalence of cancer and growing availability of cancer screening programs.
North America will remain the largest region during the forecast period due to presence of well-established healthcare systems, rising incidence of cancer, and easy accessibility to advanced healthcare technologies in the region.
Market Size Estimates: Cancer biomarkers market size estimation in terms of value ($B).
Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.
Segmentation Analysis: Cancer biomarkers market size by various segments, such as by type, cancer type, profiling technology, application, and region in terms of ($B).
Regional Analysis: Cancer biomarkers market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
Growth Opportunities: Analysis of growth opportunities in different types, cancer types, profiling technologies, applications, and regions for the cancer biomarkers market.
Strategic Analysis: This includes M&A, new product development, and competitive landscape of the cancer biomarkers market.
Analysis of competitive intensity of the industry based on Porter's Five Forces model.
Answer: The global cancer biomarkers market is expected to reach an estimated $37.7 billion by 2030.
Answer: The global cancer biomarkers market is expected to grow with a CAGR of 14.5% from 2024 to 2030.
Answer: The major drivers for this market are increasing inclination towards personalized medicine for cancer treatment, growing awareness towards importance of early detection of cancer, and rising government support for cancer research.
Answer: The future of the cancer biomarkers market looks promising with opportunities in the diagnostics, R&D, prognostics, and risk management markets.
Answer: Some of the key cancer biomarkers companies are as follows:
Answer: Lucintel forecasts that breast cancer will remain the largest segment over the forecast period due to increasing incidence of breast cancer and rising awareness of the diagnosis of this disease.
Answer: North America will remain the largest region during the forecast period due to presence of well-established healthcare systems, rising incidence of cancer, and easy accessibility to advanced healthcare technologies in the region.
Answer: Yes, Lucintel provides 10% customization without any additional cost.